496 related articles for article (PubMed ID: 18098337)
1. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
[TBL] [Abstract][Full Text] [Related]
2. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
4. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
[TBL] [Abstract][Full Text] [Related]
5. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
Preto A; Gonçalves J; Rebocho AP; Figueiredo J; Meireles AM; Rocha AS; Vasconcelos HM; Seca H; Seruca R; Soares P; Sobrinho-Simões M
BMC Cancer; 2009 Oct; 9():387. PubMed ID: 19878585
[TBL] [Abstract][Full Text] [Related]
6. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival.
Matos P; Oliveira C; Velho S; Gonçalves V; da Costa LT; Moyer MP; Seruca R; Jordan P
Gastroenterology; 2008 Sep; 135(3):899-906. PubMed ID: 18602919
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.
Oliveira C; Velho S; Moutinho C; Ferreira A; Preto A; Domingo E; Capelinha AF; Duval A; Hamelin R; Machado JC; Schwartz S; Carneiro F; Seruca R
Oncogene; 2007 Jan; 26(1):158-63. PubMed ID: 16953233
[TBL] [Abstract][Full Text] [Related]
9. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
[TBL] [Abstract][Full Text] [Related]
10. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
[TBL] [Abstract][Full Text] [Related]
12. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
[TBL] [Abstract][Full Text] [Related]
14. Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations.
Kim IJ; Kang HC; Jang SG; Kim K; Ahn SA; Yoon HJ; Yoon SN; Park JG
Carcinogenesis; 2006 Mar; 27(3):392-404. PubMed ID: 16219636
[TBL] [Abstract][Full Text] [Related]
15. BRAF is a therapeutic target in aggressive thyroid carcinoma.
Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
[TBL] [Abstract][Full Text] [Related]
16. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
[TBL] [Abstract][Full Text] [Related]
17. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
[TBL] [Abstract][Full Text] [Related]
18. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
Wish TA; Hyde AJ; Parfrey PS; Green JS; Younghusband HB; Simms MI; Fontaine DG; Dicks EL; Stuckless SN; Gallinger S; McLaughlin JR; Woods MO; Green RC
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1831-9. PubMed ID: 20570909
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
20. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]